Alaunos raises $1.12M in registered direct offering of stock and pre-funded warrants

Alaunos Therapeutics, Inc.

Sold 380,469 common shares at $1.46/share and 386,654 pre-funded warrants at $1.459 each for ~$1.12M gross.
Net proceeds approximately $915,400.50 after fees; intended for general corporate and working capital purposes.
Priced at-the-market under Nasdaq rules; Dawson James Securities acted as sole placement agent with 8% cash fee.
Offering closed September 21, 2026; pre-funded warrants exercisable at $0.001, no expiration, 4.99% beneficial ownership limit.
Officers and directors entered 15-day lock-up agreements restricting share transfers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.